Revance Therapeutics, Inc. (RVNC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 743.63M |
| Enterprise Value | 1.08B |
| P/E Ratio | -0.95 |
| PEG Ratio | -0.01 |
| Price/Sales Ratio | 1.63 |
| Price/Book Ratio | -2.04 |
| Enterprise/Revenue | 3.09 |
| Enterprise/EBITDA | -2.48 |
Fiscal Year
| Fiscal Year | December 31, 2023 |
| Most Recent Quarter | September 30, 2024 |
Profitability
| Profit Margin | -1.38 |
| Operating Margin | -1.35 |
AD
Management Effectiveness
| Return On Assets | -0.68 |
| Return On Equity | 4.66 |
Income Statement
| Revenue | 234.04M |
| Revenue/Share | 2.77 |
| Gross Profit | 81.88M |
| EBITDA | -290.64M |
| Net Income | -323.99M |
| Diluted EPS | -3.83 |
Balance Sheet
| Total Cash | 184.08M |
| Total Cash/Share | 3 |
| Total Debt | 483.45M |
| Total Debt/Equity | -3.16 |
| Current Ratio | 3.8 |
| Book Value Per Share | -1.79 |
Price History
| 52-Week Change | -39.27 |
| 52-Week High | 7.56 |
| 52-Week Low | 2.3 |
| Moving Average 50 Days | 3.39 |
| Moving Average 200 Days | 4.16 |
Statistics
| Average Volume | 2.96M |
| Shares Outstanding | 104.39M |
| % Held by Institutions | 78.66 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
